- Home
- AOMR vs XGN Comparison
AOMR vs XGN Comparison
Compare AOMR & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- XGN
- Stock Information
- Founded
- AOMR 2018
- XGN 2002
- Country
- AOMR United States
- XGN United States
- Employees
- AOMR N/A
- XGN N/A
- Industry
- AOMR Real Estate Investment Trusts
- XGN Medical Specialities
- Sector
- AOMR Real Estate
- XGN Health Care
- Exchange
- AOMR Nasdaq
- XGN Nasdaq
- Market Cap
- AOMR 224.3M
- XGN 210.4M
- IPO Year
- AOMR 2021
- XGN 2019
- Fundamental
- Price
- AOMR $9.30
- XGN $11.22
- Analyst Decision
- AOMR Strong Buy
- XGN Strong Buy
- Analyst Count
- AOMR 6
- XGN 5
- Target Price
- AOMR $11.25
- XGN $12.40
- AVG Volume (30 Days)
- AOMR 108.8K
- XGN 248.9K
- Earning Date
- AOMR 11-05-2025
- XGN 11-11-2025
- Dividend Yield
- AOMR 13.63%
- XGN N/A
- EPS Growth
- AOMR N/A
- XGN N/A
- EPS
- AOMR 1.56
- XGN N/A
- Revenue
- AOMR $57,661,000.00
- XGN $58,862,000.00
- Revenue This Year
- AOMR N/A
- XGN $22.28
- Revenue Next Year
- AOMR $12.91
- XGN $14.03
- P/E Ratio
- AOMR $6.01
- XGN N/A
- Revenue Growth
- AOMR N/A
- XGN 3.89
- 52 Week Low
- AOMR $7.36
- XGN $2.38
- 52 Week High
- AOMR $10.88
- XGN $11.17
- Technical
- Relative Strength Index (RSI)
- AOMR 39.34
- XGN 69.47
- Support Level
- AOMR $9.30
- XGN $10.63
- Resistance Level
- AOMR $9.60
- XGN $11.11
- Average True Range (ATR)
- AOMR 0.14
- XGN 0.40
- MACD
- AOMR -0.02
- XGN 0.03
- Stochastic Oscillator
- AOMR 5.62
- XGN 97.72
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.